BUZZ-RAPT Therapeutics soars as skin condition drug shows comparable efficacy to Roche's drug
I'm PortAI, I can summarize articles.
Shares of Rapt Therapeutics surged 90% to $55.64 after its experimental drug RPT904 demonstrated comparable efficacy and safety to Roche's Xolair in a mid-stage trial for chronic spontaneous urticaria (CSU). The study involved 137 patients and showed that 46% of those on RPT904 had no symptoms at week 16, compared to 33.3% on Xolair. The stock has risen approximately 132% year-to-date.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments